KDM1A and small cell lung carcinoma: The results collectively indicate that LSD1 serves as a significant regulator of MHC-I antigen presentation, supporting the hypothesis that the combination of LSD1 inhibitors and immune checkpoint blockade could enhance therapeutic responses in patients with SCLC.